Home Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population
Article
Licensed
Unlicensed Requires Authentication

Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population

  • A. Gorkem Mungan , Bulent Erol , Bulent Akduman , Gurdal Bozdogan , Sibel Kiran , Cetin Yesilli and N. Aydin Mungan
Published/Copyright: July 1, 2007
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 45 Issue 7

Abstract

Background: The aim of this study was to evaluate age-related changes in free/total prostate-specific antigen (f/t PSA) ratio, focusing on the avoidance of unnecessary prostate biopsies.

Methods: A total of 898 men aged 30–88 years without a history of prostate surgery and disease were enrolled into the study. Serum tPSA, fPSA and f/t PSA ratios were determined for the study population and for different age categories. All males who had suspicious digital rectal examination and tPSA >4 ng/mL underwent transrectal ultrasonography-guided prostate biopsy. Receiver operating characteristic (ROC) curves for each group were generated by plotting the sensitivity vs. 1–specificity for the f/t PSA ratio. The sensitivity and specificity were obtained using different f/t PSA ratio cutoffs for different age groups.

Results: Prostate cancer was detected in 63 patients (7%). Age-specific cutoffs were determined according to likelihood ratios at the levels of 10%, 15% and 15% f/t PSA ratio for ages 50–59, 60–69 and ≥70 years, respectively. However, a single cutoff of 10% is recommended across all age ranges (positive likelihood ratio 2.36). ROC curves demonstrated that the area under the curve (AUC) was significant for all patients with initial PSA of 4–10 ng/mL (AUC 0.703–0.796), except for the ≥70-year age group (AUC 0.549).

Conclusions: The current study showed that the use of f/t PSA ratio in patients with PSA levels of 4–10 ng/mL should enhance the specificity of PSA screening and decrease the number of unnecessary biopsies. f/t PSA levels may show dissimilarities according to age and ethnicity, so further studies are warranted to identify this relationship.

Clin Chem Lab Med 2007;45:912–6.


Corresponding author: Assist Prof. A. Gorkem Mungan, MD, Zonguldak Karaelmas University, School of Medicine, Department of Biochemistry, 67600 Kozlu Zonguldak, Turkey Phone: +90-533-2647658, Fax: +90-372-2610264

Received: 2006-12-12
Accepted: 2007-3-16
Published Online: 2007-07-01
Published in Print: 2007-07-01

©2007 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Pharmacogenomics and Personalized Medicine – a global reality check
  2. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice
  3. Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy
  4. Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer
  5. Effect of 13-cis-retinoic acid on the genetic expression profile of human umbilical vein endothelial cells (HUVECs) determined by microarray
  6. Association between T102C and A–1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: relevance for treatment with antipsychotic drugs
  7. A1166C polymorphism of the angiotensin AT1 receptor (AT1R) gene alters endothelial response to statin treatment
  8. Third Santorini conference pharmacogenomics workshop report: “Pharmacogenomics at the crossroads: what else than good science will be needed for the field to become part of Personalized Medicine?”
  9. On detecting interference from endogenous antibodies in immunoassays by doubling dilutions test
  10. High-sensitivity C-reactive protein concentration in patients with myocardial infarction-environmental factors, and polymorphisms in interleukin-10 and CD14 genes
  11. Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience
  12. A novel application of melting curves: utility of peak area calculation for relative methylation quantification
  13. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians
  14. Tumor necrosis factor-α and oxidant status are essential participating factors in unexplained recurrent spontaneous abortions
  15. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients
  16. Analysis of glomerular filtration rate, serum cystatin C levels, and renal resistive index values in cirrhosis patients
  17. Direct determination of selenium in human serum by inductively coupled plasma-collision cell-mass spectrometry
  18. Within-subject variation of plasma resistin levels over a 1-year period
  19. Global DNA methylation measured by liquid chromatography-tandem mass spectrometry: analytical technique, reference values and determinants in healthy subjects
  20. Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population
  21. Comparison of the Roche COBAS Amplicor™ Monitor, Roche COBAS Ampliprep™/COBAS Taqman™ and Abbott RealTime™ Test assays for quantification of hepatitis C virus and HIV RNA
  22. Genetic cystic fibrosis transmembrane regulator 4016insT D1152H compound heterozygosity and male infertility: an Italian case report
  23. Reference intervals for serum cystatin C in healthy Mexican adults
  24. Could standard ISO 15189 be useful for the conundrum of CA 19-9/GI Monitor measurement?
  25. Quality control strategy to verify day-to-day imprecision of length of blood sedimentation reaction measurements with the TEST-1 analyzer
  26. Applicability of α-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up
  27. Proposal of a candidate international conventional reference measurement procedure for free thyroxine in serum
  28. Balkan Clinical Laboratory Federation − past, present and future trends
Downloaded on 8.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2007.501/html
Scroll to top button